Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00721513 · OUTCOME

Performance Status Scale for Head and Neck Cancer

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years

What was measured

Consists of assessment of three functions (subscales): Normalcy of diet, eating in public, and understandability of speech. The interviewer rates the patient on each scale based on the patient's responses to targeted questions. Scores range from 0-100 (Full performance (100 score), moderate or severe impairment (≤ 50 score)). The higher the score, the better the ability of the patient to function.

Analysis population: Data was not collected for all participants.

Groups in this outcome

TPFChemotherapy + Concomitant Cetuximab & RT

Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT16

Reported measurements

Baseline Performance Status for Eating

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT10
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT82.5026.48Not reportedNot reportedNot reported
Baseline Performance Status for Speech

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT10
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT95.0010.54Not reportedNot reportedNot reported
Baseline Performance Status for Diet

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT9
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT84.4420.07Not reportedNot reportedNot reported
Pre-RT Performance Status for Eating

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT6
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT45.8351.03Not reportedNot reportedNot reported
Pre-RT Performance Status for Speech

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT6
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT100.000.00Not reportedNot reportedNot reported
Pre-RT Performance Status for Diet

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT6
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT41.6749.16Not reportedNot reportedNot reported
Post-RT Performance Status for Eating

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT4
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT50.0045.64Not reportedNot reportedNot reported
Post-RT Performance Status for Speech

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT4
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT93.7512.50Not reportedNot reportedNot reported
Post-RT Performance Status for Diet

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT4
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT40.0045.46Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.48
        value
        82.50
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    Baseline Performance Status for Eating
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        10.54
        value
        95.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    Baseline Performance Status for Speech
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.07
        value
        84.44
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      units
      Participants
    title
    Baseline Performance Status for Diet
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        51.03
        value
        45.83
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-RT Performance Status for Eating
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.00
        value
        100.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-RT Performance Status for Speech
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        49.16
        value
        41.67
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-RT Performance Status for Diet
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        45.64
        value
        50.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Post-RT Performance Status for Eating
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        12.50
        value
        93.75
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Post-RT Performance Status for Speech
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        45.46
        value
        40.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Post-RT Performance Status for Diet
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Consists of assessment of three functions (subscales): Normalcy of diet, eating in public, and understandability of speech. The interviewer rates the patient on each scale based on the patient's responses to targeted questions. Scores range from 0-100 (Full performance (100 score), moderate or severe impairment (≤ 50 score)). The higher the score, the better the ability of the patient to function.
dispersion Type
Standard Deviation
groups
  1. description
    Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy
    id
    OG000
    title
    TPFChemotherapy + Concomitant Cetuximab & RT
param Type
MEAN
population Description
Data was not collected for all participants.
reporting Status
POSTED
time Frame
Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years
title
Performance Status Scale for Head and Neck Cancer
type
SECONDARY
unit Of Measure
Score on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice